ReviewJournal of translational medicine2026
Computational prediction of TCR cross-reactivity: principles, challenges and translational opportunities.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
T-cell receptor (TCR) cross-reactivity, whereby a single TCR recognizes multiple peptide-MHC (pMHC) ligands, is essential for immune surveillance but also represents a major safety challenge for TCR-based therapeutics because of severe off-target toxicities. Rapid advances in immune-repertoire sequencing, structural biology, and immunopeptidomics have accelerated computational efforts to characterize cross-reactive recognition at scale. However, most existing methods are adapted from conventional TCR-pMHC specificity prediction and remain insufficiently aligned with the one-to-many, structurally plastic, and context-dependent nature of cross-reactivity. Here, we review the main data resources supporting TCR cross-reactivity modeling, including sequence- and structure-centric databases, and highlight persistent limitations, such as scarce explicitly annotated cross-reactive TCRs, strong biases toward viral epitopes and common HLA alleles, limited paired αβ-chain information, and a lack of rigorously validated negative examples. We then compare the major computational paradigms-sequence-based, structure-based, machine-learning, and multimodal approaches-with emphasis on their respective strengths and limitations in interpretability, generalization, and scalability. Finally, we discuss emerging translational applications and outline key priorities for the field, including dedicated datasets, rigorous benchmarking, and biologically grounded multimodal models to enable safer and more clinically actionable TCR-based immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.